Mucolator

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucolator

Property Description
Active ingredient Acetylcysteine (NAC)
Form Solution, Effervescent tablet, Injectable
Pharmacological class Mucolytic Agent, Systemic Antidote
Common use Facilitating respiratory clearance
Origin Synthetic N-acetyl derivative

What Type of Medicine is Mucolator?

Mucolator is a pharmaceutical product containing the active ingredient Acetylcysteine (NAC), which is formally classified as both a direct-acting mucolytic agent and, critically, a systemic antidote. Its identity is that of a specialized, single-ingredient compound whose dual categorization is clinically recognized for addressing distinct therapeutic needs. Mucolator is positioned as a prescription-only product intended for individuals requiring effective management of tenacious respiratory secretions or systemic detoxification.

Is Acetylcysteine Natural or Synthetic, and How is it Administered?

The active component, Acetylcysteine, is a synthetic N-acetyl derivative of the semi-essential amino acid L-Cysteine, characterized by a crucial free sulfhydryl group. Mucolator is manufactured in specialized physical forms, including sterile solutions for inhalation, effervescent tablets for oral administration, and specialized injectable solutions for intravenous use. This comprehensive range of preparations and corresponding routes—oral, inhalation, and intravenous—is supported by pharmacological studies confirming its absorption capabilities in these varied formats.

What is the Primary General Benefit of this Component?

The general benefit of Acetylcysteine is two-fold: it helps the patient achieve easier clearance of thick respiratory mucus and supports the maintenance of essential cellular defense mechanisms. It functions by chemically targeting and breaking the disulfide bonds within highly viscid mucus, thereby reducing its consistency and facilitating airway clearance. Furthermore, through its well-established role as a precursor to glutathione (GSH), it provides a necessary component to help support the body's antioxidant system, a critical function that has received significant clinical recognition for its use in acute toxic exposures.

Regulatory References

  1. NIH National Library of Medicine
  2. MedlinePlus Drugs and Supplements

What side effects are possible with Mucolator?

Possible side effects and safety information

The safety profile for Mucolator (Acetylcysteine) is categorized according to official regulatory standards, classifying potential adverse reactions by the body system affected and their reported frequency. Effects frequently involve the immune and gastrointestinal systems.

Regulatory Classification of General Adverse Reactions

Adverse reactions are classified by frequency as listed in regulatory documents such as the Summary of Product Characteristics (SmPC):

Frequency Tier Example Adverse Reactions (SOC Grouping)
Uncommon (geq1/1,000 to < 1/100) Hypersensitivity, Headache, Tinnitus, Tachycardia, Nausea, Vomiting, Abdominal pain, Urticaria, Fever.
Rare (geq1/10,000 to < 1/1,000) Bronchospasm, Dyspnoea, Dyspepsia.
Very Rare (< 1/10,000) Anaphylactic shock, Anaphylactic/Anaphylactoid reaction, Haemorrhage.

Serious Adverse Reactions and System-Specific Effects

Serious Adverse Reactions documented in official labeling include anaphylactic shock and other severe anaphylactoid reactions. Severe mucocutaneous reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have also been reported in temporal association with the use of Acetylcysteine.

Effects on the Vascular system include hypotension (low blood pressure), and the Nervous system reports include syncope (fainting) and generalized seizure.

Contextual and Population-Specific Safety Patterns

Adverse reactions, particularly hypersensitivity responses, are reported to occur most frequently at the beginning of treatment or shortly after the initiation of intravenous administration. Safety constraints specify that caution is advised for patients with a history of peptic ulcers or a history of asthma or bronchospasm. Furthermore, the concurrent administration of Acetylcysteine with nitroglycerin is noted to potentially result in significant hypotension.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is derived strictly from official government regulatory documents regarding the overdose profile of Acetylcysteine (Mucolator).

Overdose Manifestations and Severe Outcomes

Excessive administration of Mucolator, particularly via the intravenous route, is officially documented to cause a variety of systemic and cardiovascular signs. Documented manifestations include nausea, vomiting, diarrhea, skin flushing, sweating, and headache. More severe clinical signs can include hypotension (low blood pressure) and tachycardia (increased heart rate). Life-threatening outcomes, such as anaphylactoid reactions and cardiovascular collapse, are formally noted in regulatory prescribing information.

Mandated Emergency Action and Management

The regulatory guidance is explicit that immediate medical attention must be sought, or emergency services contacted immediately, upon suspicion of an overdose or development of a severe reaction. Treatment must be immediately discontinued upon the onset of a serious systemic event. Management of Acetylcysteine overdose is based solely on symptomatic and supportive measures, as no specific pharmacological antidote is known. Supportive treatment may include administration of intravenous antihistamines and corticosteroids for severe reactions, and continuous cardiorespiratory monitoring is required.

Therapeutic Uses of Mucolator

Mucolator (Acetylcysteine) is commonly used across two distinct areas: supportive management of severe, obstructive respiratory secretions and providing antidote support in acute toxicity contexts.

Acetylcysteine is commonly used to help manage certain lung conditions when increased amounts of mucus make breathing difficult, and may also assist in helping to prevent or lessen the severity of liver damage caused by an overdose of acetaminophen.

This medication is applied when patients experience symptoms related to thick and persistent phlegm in conditions such as Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and Cystic Fibrosis. It is also relevant when supportive symptom management is appropriate for acute toxic ingestions involving acetaminophen (paracetamol). The primary benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“The primary benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Thick Mucus and Congestion


Easing Symptomatic Burden in Chronic Lung Conditions

This medication is commonly used across conditions characterized by periods of heightened symptoms related to a high burden of thick, tenacious phlegm. It is applied when groups of symptoms, including chest congestion and an ineffective cough, create noticeable physiological strain. The key benefit is that it supports the management of difficult-to-clear mucus, contributing to improved expectoration and helping patients cope more steadily with symptom fluctuations.


Providing Organ Protection in Acute Toxic Exposure

Mucolator is an important therapeutic intervention applied in clinical settings that involve acute or disruptive symptom patterns, specifically for individuals who have ingested a potentially toxic quantity of acetaminophen (paracetamol). This use is relevant in contexts involving heightened systemic burden linked to organ-specific functional stress and is applied when appropriate in settings where short-term symptomatic assistance is needed. In this context, the medication's primary benefit is offering supportive relief that may assist with preventing or reducing the severity of liver damage following the specific acute toxic exposure.

Regulatory References

  1. Acetylcysteine Oral Inhalation: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Mucolator (Acetylcysteine)

This section defines population eligibility based strictly on official government regulatory documents (e.g., FDA, EMA-affiliated agencies).

Populations Not Eligible (Contraindications)

  • Hypersensitivity: Mucolator is strictly contraindicated in patients with a known allergy or documented hypersensitivity reaction to acetylcysteine or any other ingredients (excipients) in the specific product formulation.
  • Phenylketonuria (PKU): Certain oral formulations are contraindicated for patients with PKU if the product contains phenylalanine (aspartame).
  • Pediatric Age: Specific oral formulations are contraindicated for use in children under 2 years of age.

Restricted or Conditional Use

Condition / Status Restriction
Asthma / Bronchospasm Use with caution due to increased risk of hypersensitivity reactions, including severe bronchospasm.
Pregnancy / Lactation Not recommended unless clearly necessary, due to insufficient data to establish safety.
Stomach/Duodenal Ulcers Use is not recommended for certain oral formulations.
Age Restriction Specific oral formulations are not recommended for children under 12 years of age.

Eligibility may also be restricted for patients with renal or hepatic impairment as full pharmacokinetic data is often unavailable for these groups.

What should I know about interactions with other medicines?

The official regulatory profile for Mucolator (Acetylcysteine) is categorized by interactions that require strict timing separation, alter chemical exposure, or modify risk assessment.

Pharmacodynamic and Restriction Interactions

Co-administration with Nitroglycerin and other organic nitrates is documented to increase the risk of significant hypotension due to a potentiation of vasodilator effects. The combination with antitussive drugs (cough suppressants) is advised against due to a structural conflict: reducing the cough reflex may lead to the retention of the bronchial secretions that Mucolator works to thin.

Exposure and Timing Constraints

Specific administration rules govern co-use with other medicinal products. If Activated Charcoal has been given, regulatory documentation advises stomach lavage before initiating Mucolator treatment to counteract the documented risk of reduced effectiveness through adsorption. Furthermore, oral antibiotics, including certain cephalosporins, require separation of administration by at least two hours to prevent in vitro inactivation. Co-use with Carbamazepine is also officially associated with an increased risk of certain side effects.

Risk Assessment Modifiers

In its application as a systemic antidote, the official label defines factors that modify toxicity risk interpretation. The presence of CYP2E1 enzyme-inducing drugs or a patient history of chronic alcoholism are conditions that may cause the standard nomogram to underestimate the potential for liver injury.

Mechanism of Action

How Mucolator Works: Mechanism of Action


Chemically Reducing Mucus Viscosity

Mucolator acts primarily through a thiol-disulfide interchange reaction, where its free —SH group cleaves the disulfide bonds that cross-link mucin glycoproteins. This chemical alteration rapidly depolymerizes the mucin matrix, causing a decrease in the mucus's viscosity and elasticity, enabling the movement of the thinned secretions by the mucociliary system.


Modulating Oxidative Stress in Airways

The molecule also engages the antioxidant defense system by directly scavenging highly reactive oxygen species (ROS) in the respiratory tract. Furthermore, it acts as a precursor for reduced glutathione (GSH) synthesis, increasing the availability of reduced glutathione. This mechanism supports the regulation of oxidative stress pathways, influencing pathways associated with inflammatory mediators and epithelial oxidative stress.

Dosage and Administration Information

Mucolator, which contains Acetylcysteine, is prepared for administration across several officially approved routes depending on the specific use pattern. The medicine is provided as an inhalation/instillation solution, an oral solution or effervescent tablet, or an intravenous (IV) infusion.

The medicine is governed by two distinct sets of protocols. For respiratory clearance, the solution is typically administered via nebulization, with the standard regimen involving 3 to 5 mL of a 20% solution or 6 to 10 mL of a 10% solution. This delivery is generally scheduled on an intermittent basis, such as 3 to 4 times daily, or every 2 to 6 hours.

For its systemic antidote application, the use is strictly managed under a fixed, weight-based sequence. The intravenous (IV) regimen involves a total of 300 mg/kg administered over a 21-hour course, which is divided into three consecutive infusions. The oral antidote protocol consists of 18 doses over approximately 72 hours, starting with a 140 mg/kg loading dose followed by 17 maintenance doses of 70 mg/kg every 4 hours.

Preparation is a mandatory step for systemic use; the injectable concentrate must be diluted in specified intravenous fluids, and the oral solution must also be diluted and used within one hour of its preparation. Administration rules for specific populations include applying a ceiling weight (e.g., 100 kg) when calculating doses for larger patients, and reducing total fluid volume for patients weighing 40 kg or less.

Recent Clinical Evidence

Research evidence / Overview of studies for Mucolator


Evidence for Use as an Antidote in Acute Toxicity

Mucolator (Acetylcysteine) was studied for its role as an antidote in managing acute, excessive ingestion of acetaminophen. The research primarily consists of systematic reviews and meta-analyses of patient outcomes, alongside historical data. This evidence describes the medicine's classification as a systemic antidote and the research context. These studies were evaluated in human participants, including adults and children, often categorized by the amount of time that passed between the ingestion and the start of treatment.

Research examined the risk of hepatotoxicity (liver injury) and the mortality rate of patients. The findings describe patterns observed in the studies that monitored a relationship between the early administration of this medicine and patterns related to a lower incidence of hepatotoxicity compared to historical data sets. Meta-analyses reported measurements that indicated a lower mortality and lower need for liver transplantation in the treated group compared to historical controls. While this area of research describes a consistent body of evidence, the optimal dosing for extremely large ingestions is not fully established, and comparative evidence is lacking for the effectiveness of intravenous versus oral routes.


Research on Long-Term Support in Chronic Lung Conditions

Mucolator was evaluated in trials exploring long-term support for individuals with chronic lung conditions like Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, which are conditions characterized by fluctuating symptoms. The research base consists mainly of long-term randomized controlled trials (RCTs) that followed adults for periods ranging from one to three years.

Studies explored outcomes such as the annual frequency of flare-ups (exacerbations) and changes in lung function (measured by FEV1) over the study period. Findings were mixed across major trials. Some studies reported patterns where the frequency of flare-ups was lower in groups taking the medicine compared to placebo, particularly where high doses were observed. However, other large-scale trials reported no significant difference in the overall rate of exacerbations or the progression of lung function decline between the study and control groups.

Uncertainty remains due to the inconsistent findings across these major long-term RCTs, particularly regarding long-term changes in the rate of lung function decline. Evidence quality varies across studies, and there is limited information to characterize the potential effects of low-dose regimens compared to high doses.

Key Studies & References N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review

Frequently Asked Questions (FAQ)

Common questions about Mucolator (FAQ)


Q: Can Mucolator be used for coughs not related to its main purpose?

A: Regulatory documents state that Mucolator's approved use is as an adjuvant therapy. Its purpose is to facilitate mucolysis (thinning of mucus) for specific conditions characterized by abnormal, thick, or viscid mucous secretions, such as chronic or acute bronchitis.


Q: How long does it usually take to feel the effects of Mucolator?

A: According to official information on pharmacokinetics, the maximum concentration of the medicine in the blood is typically reached within one to two hours after taking an oral dose. The loosening of thick bronchial secretions may be expected to occur shortly after administration.


Q: Can a person stop taking Mucolator suddenly, or does it require a gradual approach?

A: For its use as an antidote, discontinuation is based on strict medical protocols, such as completing the treatment course or meeting specific clinical criteria. Discontinuation protocols are often patient-specific, depending on the reason for use, and regulatory documents do not provide general tapering instructions.


Q: Is Mucolator safe to use if I have kidney issues?

A: Official eligibility information notes that use may be restricted for patients with existing kidney (renal) or liver (hepatic) impairment. This is often noted because full data on how the drug is processed in these specific groups may not be available. Monitoring of renal function is recommended during certain treatments.


Q: How should Mucolator be stored at home?

A: Storage guidelines depend on the specific dosage form. For example, effervescent tablets must be kept below 30 C and protected from moisture in their original container. Unopened solution vials must not be frozen. All forms of the medicine must be kept out of the sight and reach of children.


Q: What happens if I accidentally take too much Mucolator?

A: In the event of a suspected overdose, official regulatory advice requires contacting a Poison Control Center or emergency services immediately.


Q: Are there different forms of Mucolator (e.g., tablet, liquid, extended-release)?

A: The medicine is supplied in several forms, including solutions for inhalation and intravenous infusion, and as effervescent tablets for oral administration. Official documents do not describe a specific extended-release formulation.


Q: Can Mucolator cause any changes in mood or behavior?

A: Changes in mood or behavior are not explicitly listed in the common adverse event tables. However, the official safety profile includes central nervous system effects such as headache, drowsiness, and presyncope (a fainting sensation).


Q: What does the research say about Mucolator's side effect profile?

A: Research reviews have noted that the medicine is typically associated with a minimal risk of adverse events. The most commonly reported adverse reactions found in studies involve the gastrointestinal system, such as nausea and vomiting, especially with oral use.


Q: Is Mucolator appropriate for use by children?

A: Official labeling indicates that the medicine is documented for use in both adult and pediatric populations. However, specific oral formulations are strictly contraindicated (not allowed) for children under 2 years of age due to potential risks to the airways.


Q: Can I use Mucolator while taking birth control pills?

A: Official labeling does not list a specific known interaction between Mucolator and hormonal contraceptives (birth control pills). Information about all medicines and supplements being used is necessary for accurate clinical review.


Q: What are the official guidelines regarding Mucolator use during pregnancy?

A: The medicine is classified as Pregnancy Category B. Animal studies have not shown risk to the fetus, but there are insufficient controlled studies in pregnant women. Regulatory documents state that use during pregnancy is conditional and is generally restricted to situations where it is considered necessary.


Q: What does the official guidance say about using Mucolator while breastfeeding?

A: It is not known whether the active component is excreted into human breast milk. Official guidance describes the necessity for careful consideration of potential benefits and risks prior to use during breastfeeding.


Q: Is Mucolator a narcotic or controlled substance?

A: Mucolator (Acetylcysteine) is not classified as a narcotic or a federally controlled substance by the U.S. DEA. It is regulated as a prescription-only medicine.


Q: Does Mucolator interact with common vitamins or supplements?

A: Official labeling does not list specific known interactions with common vitamins or general supplements. The necessity of informing a healthcare professional about all medicines and supplements being used is a standard component of regulatory guidance.


Q: Is it normal to feel slightly dizzy when first starting Mucolator?

A: Dizziness is not explicitly listed as a frequent side effect in the official documents. However, related adverse events such as presyncope (fainting sensation) have been reported in some regulatory documentation.


Q: Are there any specific foods or drinks that should be avoided while using Mucolator?

A: Official information does not list any specific foods or drinks that must be avoided. The oral solution form is sometimes diluted with a soft drink or juice for administration to improve palatability.


Q: Is Mucolator a long-term or short-term medication?

A: The medicine is used on a short-term basis for antidote protocols, which may last 21 to 72 hours. It has also been studied in long-term regimens for chronic lung conditions, with trials lasting one to three years.


Q: Are there any known interactions between Mucolator and alcohol?

A: Official labeling notes that a patient history of chronic alcoholism may modify the interpretation of the risk for liver injury when the medicine is used as a systemic antidote. A general interaction with moderate alcohol consumption is not listed.


Q: Is there a generic version of Mucolator available?

A: The active ingredient in Mucolator, Acetylcysteine, is available in generic form from multiple manufacturers under its chemical name. The active ingredient, Acetylcysteine, is the generic component of the branded medicine.


Q: Can Mucolator cause insomnia or affect my sleep schedule?

A: Insomnia is not explicitly listed in common side effect profiles in the official documents. However, other central nervous system effects, such as drowsiness, have been reported.


Q: Is Mucolator considered safe for the elderly population?

A: Official regulatory documents include specific sections on use in the geriatric (elderly) population, which do not list a general contraindication. Use is conditional, based on the individual patient's condition, similar to the general population.


Q: How is Mucolator eliminated from the body?

A: The drug is primarily metabolized (broken down) in the body. The resulting derivatives, such as cysteine and mercapturic acid, are then excreted (removed) by the kidney. A small fraction of the medicine is excreted unchanged in the urine.


Q: What is the half-life of Mucolator?

A: The half-life (t1/2) is the time it takes for half the medicine to be eliminated from the body. Studies report the terminal half-life of the active component in the blood to be approximately 6 hours, with some population-specific values ranging up to 18.7 hours depending on the population studied.


Q: Does Mucolator lose effectiveness over time?

A: Research on the long-term use of the medicine in chronic lung conditions has produced mixed findings across major clinical trials regarding its effectiveness in reducing exacerbations or slowing lung function decline.


Q: Does Mucolator interact with any common over-the-counter pain relievers?

A: Official documentation does not list specific known interactions with common over-the-counter pain relievers (like acetaminophen). Interaction review requires informing a healthcare professional of all medicines being used.


Q: Can Mucolator affect my ability to drive or operate machinery?

A: Official patient information states that there are no data available on the medicine’s effect on the ability to drive or operate machinery. The official documentation notes that an effect on driving ability is considered unlikely.


Q: If I have a history of liver problems, is Mucolator still an option?

A: Official information advises caution for patients with a history of liver (hepatic) problems. Eligibility may be restricted due to limited pharmacokinetic data, and liver function is routinely monitored during its use as an antidote.


Q: What is the proper way to dispose of unused Mucolator?

A: Unused or expired medication must not be thrown away with household waste or poured down the drain. Disposal must be conducted in accordance with local regulations, and this often involves returning it to a pharmacist for safe disposal.


Q: Does Mucolator have a specific classification under international drug scheduling?

A: In some regulatory territories, the medicine is classified as Schedule II. This designation means it is available only with a prescription and requires specific management by a healthcare professional.


Q: What is the difference between a liquid and a tablet formulation of Mucolator?

A: The primary difference relates to the route of administration. Liquid forms are solutions intended for use in specific routes, such as nebulization or intravenous infusion, which require dilution. Tablets are effervescent and intended only for oral administration.


Q: Do official documents mention any expected long-term effects of using Mucolator?

A: The official safety profile focuses on known adverse reactions and contraindications. While research has examined its use over one to three years for chronic conditions, the official documents do not contain a general summary of 'expected' long-term effects beyond the established safety data.


Q: Can Mucolator be taken with herbal remedies like St. John's Wort?

A: Official labeling does not list a specific known interaction with the herbal remedy St. John's Wort. Regulatory guidance requires informing a healthcare professional about all herbal products and supplements being used.

How should Mucolator be stored and disposed of?

How to Store and Dispose of Mucolator?

The official storage and disposal guidelines for Mucolator (Acetylcysteine) are based on the specific dosage form.

  • Temperature and Protection: Effervescent tablets and powders must be stored below 30 C and kept in the original container, tightly closed, to protect them from moisture and light. Unopened solution vials are generally stored at controlled room temperature (mathbf20^circ to mathbf25 C) or may be refrigerated, but they must not be frozen.

  • In-Use Stability: After opening, undiluted solution remaining in a vial must be refrigerated and discarded after 96 hours (4 days). Diluted solutions prepared for administration must be used within one hour and cannot be stored.

  • Handling and Child Safety: The solution can be inactivated by contact with certain metals (iron, copper, nickel) or rubber, requiring specific delivery equipment. All forms of this medicine must be kept out of the sight and reach of children.

  • Disposal Rules: Unused or expired medication must not be thrown away with household waste or poured down the drain. Disposal must be performed in accordance with local regulations or by consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucolator found in:

A-Z Index: